ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry

Molecular Oncology

Volumn 6, Issue 4, 2012, Pages 428-436

  Laenkholm, Anne Vibeke ^a,h   Knoop, Ann ^b,h   Ejlertsen, Bent ^c,d,h   Rudbeck, Tine ^e,h   Jensen, Maj Britt ^d   Müller, Sven ^e   Lykkesfeldt, Anne Elisabeth ^f,h   Rasmussen, Birgitte Bruun ^g,h   Nielsen, Kirsten Vang ^e  

^a SLAGELSE HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

^d Danish Breast Cancer Cooperative Group Registry   (Denmark)

^e AGILENT TECHNOLOGIES   (United States)

^f DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^g GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^h Danish Breast Cancer Cooperative Group (DBCG) Registry   (Denmark)

Author keywords

ER; ESR1; Estrogen receptor; FISH; Immunohistochemistry

Indexed keywords

DEXTRAN; ESTROGEN RECEPTOR ALPHA;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER PATIENT; CONTROLLED STUDY; CYTOSOL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LIGAND BINDING; MAJOR CLINICAL STUDY; PLOIDY; PRIORITY JOURNAL; PROTEIN CONTENT;

EID: 84864322363     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.04.003     Document Type: Article

References (38)

1. Albertson D.G. Conflicting evidence on the frequency of ESR1 amplification in breast cancer. Nat. Genet. 2008, 40:821-822.
2. Allred D.C., Carlson R.W., Berry D.A., Burstein H.J., Edge S.B., Goldstein L.J., Gown A., Hammond M.E., Iglehart J.D., Moench S., Pierce L.J., Ravdin P., Schnitt S.J., Wolff A.C. NCCN task force report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J. Natl. Compr. Canc Netw. 2009, 7(Suppl. 6):S1-S21. quiz S22-23.
3. Brown L.A., Hoog J., Chin S.F., Tao Y., Zayed A.A., Chin K., Teschendorff A.E., Quackenbush J.F., Marioni J.C., Leung S., Perou C.M., Neilsen T.O., Ellis M., Gray J.W., Bernard P.S., Huntsman D.G., Caldas C. ESR1 gene amplification in breast cancer: a common phenomenon?. Nat. Genet. 2008, 40:806-807. author reply 810-802.
4. Burkhardt L., Grob T.J., Hermann I., Burandt E., Choschzick M., Janicke F., Muller V., Bokemeyer C., Simon R., Sauter G., Wilczak W., Lebeau A. Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res. Treat. 2010, 123:757-765.
5. Callagy G., Pharoah P., Chin S.F., Sangan T., Daigo Y., Jackson L., Caldas C. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J. Pathol. 2005, 205:388-396.
6. Davies C., Godwin J., Gray R., Clarke M., Cutter D., Darby S., McGale P., Pan H.C., Taylor C., Wang Y.C., Dowsett M., Ingle J., Peto R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784.
7. DeSombre E.R., Carbone P.P., Jensen E.V., McGuire W.L., Wells S.A., Wittliff J.L., Lipsett M.B. Special report. Steriod receptors in breast cancer. N. Engl. J. Med. 1979, 301:1011-1012.
8. Drury S., Detre S., Leary A., Salter J., Reis-Filho J., Barbashina V., Marchio C., Lopez-Knowles E., Ghazoui Z., Habben K., Arbogast S., Johnston S.R., Dowsett M. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr. Relat. Cancer 2011, 18:565-577.
9. Drury, S., Lambros, M., Marchio, C., Johnson, N., Salter, J., Levey, P., Fletcher, O., Peto, J., Reis-Filho, J., Dowsett, M., 2007. Gene copy number variability of oestrogen receptor alpha in breast cancer, San Antonio Breast Cancer Symposium. Breast Cancer Res Treat 106, p. (abstr 404).
10. Dunbier A.K., Anderson H., Ghazoui Z., Lopez-Knowles E., Pancholi S., Ribas R., Drury S., Sidhu K., Leary A., Martin L.A., Dowsett M. ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1. PLoS Genet. 2011, 7:e1001382.
11. Ejlertsen B., Aldridge J., Nielsen K.V., Regan M.M., Henriksen K.L., Lykkesfeldt A.E., Muller S., Gelber R.D., Price K.N., Rasmussen B.B., Viale G., Mouridsen H. Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. Ann. Oncol 2011, Epub ahead of print. Oct 12. 2011.
12. Ejlertsen B., Nielsen K., Rasmussen B., Jensen M.-B., Møller S., Balslev E., Müller S., Mouridsen H. Relationship between ESR1 copy number and ER expression in the DBCG 89D trial. Breast Cancer Res. Treat. 2007, 106. abstr 403.
13. EORTC, B.C.C.G. Standards for the assessment of estrogen receptors in human breast cancer. Eur. J. Cancer 1973, 9:379-381. Report of a workshop on September 29, 1972, at the Antoni van Leeuwenhoek-Huis, Amsterdam.
14. Grabau D.A., Thorpe S.M., Knoop A., Vach W., Schroder H.D., Blichert-Toft M., Al-Suliman N.N., Graversen H.P., Rose C. Immunohistochemical assessment of oestrogen and progesterone receptors: correlations with the DCC method and clinical outcome in primary breast cancer patients. Breast 2000, 9:208-217.
15. Hammond M.E., Hayes D.F., Dowsett M., Allred D.C., Hagerty K.L., Badve S., Fitzgibbons P.L., Francis G., Goldstein N.S., Hayes M., Hicks D.G., Lester S., Love R., Mangu P.B., McShane L., Miller K., Osborne C.K., Paik S., Perlmutter J., Rhodes A., Sasano H., Schwartz J.N., Sweep F.C., Taube S., Torlakovic E.E., Valenstein P., Viale G., Visscher D., Wheeler T., Williams R.B., Wittliff J.L., Wolff A.C. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 2010, 28:2784-2795.
16. Harvey J.M., Clark G.M., Osborne C.K., Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 1999, 17:1474-1481.
17. Henriksen K.L., Rasmussen B.B., Lykkesfeldt A.E., Moller S., Ejlertsen B., Mouridsen H.T. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer. Acta Oncol. 2009, 48:522-531.
18. Holst F., Stahl P.R., Ruiz C., Hellwinkel O., Jehan Z., Wendland M., Lebeau A., Terracciano L., Al-Kuraya K., Janicke F., Sauter G., Simon R. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat. Genet. 2007, 39:655-660.
19. Horlings H.M., Bergamaschi A., Nordgard S.H., Kim Y.H., Han W., Noh D.Y., Salari K., Joosse S.A., Reyal F., Lingjaerde O.C., Kristensen V.N., Borresen-Dale A.L., Pollack J., van de Vijver M.J. ESR1 gene amplification in breast cancer: a common phenomenon?. Nat. Genet. 2008, 40:807-808. author reply 810-802.
20. Iwamoto T., Booser D., Valero V., Murray J.L., Koenig K., Esteva F.J., Ueno N.T., Zhang J., Shi W., Qi Y., Matsuoka J., Yang E.J., Hortobagyi G.N., Hatzis C., Symmans W.F., Pusztai L. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J. Clin. Oncol. 2012, 30:729-734.
21. Khoshnoud M.R., Lofdahl B., Fohlin H., Fornander T., Stal O., Skoog L., Bergh J., Nordenskjold B. Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen. Breast Cancer Res. Treat. 2011, 126:421-430.
22. Knoop A.S., Bentzen S.M., Nielsen M.M., Rasmussen B.B., Rose C. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J. Clin. Oncol. 2001, 19:3376-3384.
23. Moelans C.B., de Weger R.A., van Blokland M.T., van der Wall E., van Diest P.J. Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Mod. Pathol. 2010, 23:62-70.
24. Moelans C.B., Monsuur H.N., de Pinth J.H., Radersma R.D., de Weger R.A., van Diest P.J. ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Anal. Cell Pathol. (Amst) 2010, 33:13-18.
25. Nielsen K.V., Ejlertsen B., Moller S., Jensen M.B., Balslev E., Muller S., Knoop A., Mouridsen H.T. Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status. Mol. Oncol. 2011, 6:88-97.
26. Nielsen K.V., Ejlertsen B., Muller S., Moller S., Rasmussen B.B., Balslev E., Laenkholm A.V., Christiansen P., Mouridsen H.T. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res. Treat. 2011, 127:345-355.
27. Nielsen K.V., Müller S., Poulsen T.S., Gabs S., Schonau A. Combined use of PNA and DNA for fluorescence in situ hybridization (FISH). Peptide Nucleic Acids: Protocols and Applications 2004, 227-260. Horizon Bioscience, Norfolk. second ed. P.E. Nielsen (Ed.).
28. Olsen K.E., Knudsen H., Rasmussen B.B., Balslev E., Knoop A., Ejlertsen B., Nielsen K.V., Schonau A., Overgaard J. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol. 2004, 43:35-42.
29. Ooi A., Inokuchi M., Harada S., Inazawa J., Tajiri R., Kitamura S.S., Ikeda H., Kawashima H., Dobashi Y. Gene amplification of ESR1 in breast cancers-fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study. J. Pathol. 2011, Epub ahead of print. Dec 13, 2011.
30. Regan M.M., Viale G., Mastropasqua M.G., Maiorano E., Golouh R., Carbone A., Brown B., Suurkula M., Langman G., Mazzucchelli L., Braye S., Grigolato P., Gelber R.D., Castiglione-Gertsch M., Price K.N., Coates A.S., Goldhirsch A., Gusterson B. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J. Natl. Cancer Inst. 2006, 98:1571-1581.
31. Reis-Filho J.S., Drury S., Lambros M.B., Marchio C., Johnson N., Natrajan R., Salter J., Levey P., Fletcher O., Peto J., Ashworth A., Dowsett M. ESR1 gene amplification in breast cancer: a common phenomenon?. Nat. Genet. 2008, 40:809-810. author reply 810-802.
32. Schuur E.R., Weigel R.J. Monoallelic amplification of estrogen receptor-alpha expression in breast cancer. Cancer Res. 2000, 60:2598-2601.
33. Talman M.L., Rasmussen B.B., Andersen J., Christensen I.J. Estrogen receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications. Acta Oncol. 2008, 47:789-794.
34. Thorpe S.M., Christensen I.J., Rasmussen B.B., Rose C. Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. Eur. J. Cancer 1993, 29A:971-977.
35. Tomita S., Zhang Z., Nakano M., Ibusuki M., Kawazoe T., Yamamoto Y., Iwase H. Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci. 2009, 100:1012-1017.
36. Viale G., Regan M.M., Maiorano E., Mastropasqua M.G., Dell'Orto P., Rasmussen B.B., Raffoul J., Neven P., Orosz Z., Braye S., Ohlschlegel C., Thurlimann B., Gelber R.D., Castiglione-Gertsch M., Price K.N., Goldhirsch A., Gusterson B.A., Coates A.S. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J. Clin. Oncol. 2007, 25:3846-3852.
37. Vincent-Salomon A., Raynal V., Lucchesi C., Gruel N., Delattre O. ESR1 gene amplification in breast cancer: a common phenomenon?. Nat. Genet. 2008, 40:809. author reply 810-802.
38. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M., Hayes D.F. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007, 25:118-145.